Hardy Zhou

Cooley advised Scribble Ventures, an early-stage venture firm that invests in pre-seed artificial intelligence (AI) companies, on the close of its $80 million third fund.

Cooley advised VISEN Pharmaceuticals, a late-stage, near-commercialization biopharmaceutical company focused on providing treatments for select endocrine diseases in Greater China (including Hong Kong, Macau and Taiwan), on its HK$783 million (approximately US$101 million) initial public offering (IPO) on the Stock Exchange of Hong Kong, subject to the exercise of a 15% overallotment option.

Cooley represented Andreessen Horowitz (a16z), a Silicon Valley-based venture capital firm that backs bold entrepreneurs building the future through technology, on the $500 million closing of its Biotech Ecosystem Venture Fund – a newly formed, first-of-its-kind venture capital fund to fuel broader innovation in human health.

Cooley advised Brigit, a financial health technology company, on its definitive agreement to be acquired by Upbound Group (Nasdaq: UPBD), a technology- and data-driven leader in accessible and inclusive financial products that address the evolving needs and aspirations of underserved consumers, for total consideration of up to $460 million.